INHIBITION OF STRUCTURAL JOINT DAMAGE WITH UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS

被引：0
|
作者：
Peterfy, Charles G. [1 ]
Genovese, Mark C. [2 ]
Song, In-Ho [3 ]
Friedman, Alan [3 ]
Hall, Stephen [4 ]
Mysler, Eduardo [5 ]
Durez, Patrick [6 ]
Baraliakos, Xenofon [7 ]
Enejosa, Jeffrey V. [3 ]
Shaw, Tim [3 ]
Li, Yihan [3 ]
Chen, Su [3 ]
Strand, Vibeke [2 ]
机构：
[1] Spire Sci Inc, Kentfield, CA USA
[2] Stanford Univ, Palo Alto, CA 94304 USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Monash Univ, Cabrini Hlth & Emeritus Res, Malvern, Australia
[5] Org Med Invest, Buenos Aires, DF, Argentina
[6] Catholic Univ Louvain, Clin Univ St Luc, Brussels, Belgium
[7] Herne & Ruhr Univ, Bochum, Germany
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2020年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
128
引用
收藏
页码：9 / 10
页数：2
相关论文
共 50 条
  • [31] A COMPARATIVE ANALYSIS OF UPADACITINIB MONOTHERAPY AND UPADACITINIB COMBINATION THERAPY FOR THE TREATMENT OF RHEUMATOID ARTHRITIS FROM TWO PHASE 3 TRIALS
    Buch, Maya
    Wells, Alvin F.
    Rubbert-Roth, Andrea
    Jain, Manish
    Schlacher, Casey
    Camp, Heidi
    Li, Yihan
    Song, Yanna
    Nash, Peter
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 356 - 356
  • [32] Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis
    Qiu, Qi
    Huang, Jing
    Lin, Yang
    Shu, Xiaoming
    Fan, Huizheng
    Tu, Zhihua
    Zhou, Youwen
    Xiao, Cheng
    MEDICINE, 2017, 96 (11)
  • [33] A Comparative Analysis of Upadacitinib Monotherapy and Upadacitinib Combination Therapy for the Treatment of Rheumatoid Arthritis from Two Phase 3 Trials
    Buch, Maya H.
    Wells, Alvin F.
    Rubbert-Roth, Andrea
    Jain, Manish
    Schlacher, Casey
    Camp, Heidi
    Li, Yihan
    Song, Yanna
    Nash, Peter
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [34] INHIBITION OF STRUCTURAL JOINT DAMAGE WITH UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH MTX IN PATRIENTS WITH RA: ONE-YEAR OUTCOMES FROM THE SELECT PHASE 3 PROGRAMME
    Peterfy, Charles
    Genovese, Mark C.
    Song, In-Ho
    Friedman, Alan
    Hall, Stephen
    Mysler, Eduardo
    Durez, Patrick
    Baraliakos, Xenofon
    Enejosa, Jose Jeffrey
    Shaw, Tim
    Li, Yihan
    Chen, Su
    Strand, Vibeke
    RHEUMATOLOGY, 2020, 59
  • [35] Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study
    Gaubitz, Markus
    Goettl, Karl-Heinz
    Behmer, Olaf
    Lippe, Ralph
    Meng, Thomas
    Loechmann, Peter-Andreas
    CLINICAL RHEUMATOLOGY, 2017, 36 (09) : 1989 - 1996
  • [36] Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study
    Markus Gaubitz
    Karl-Heinz Göttl
    Olaf Behmer
    Ralph Lippe
    Thomas Meng
    Peter-Andreas Löschmann
    Clinical Rheumatology, 2017, 36 : 1989 - 1996
  • [37] Structural joint damage and hand bone loss in patients with rheumatoid arthritis
    Ornbjerg, Lykke Midtboll
    DANISH MEDICAL JOURNAL, 2018, 65 (03):
  • [38] Consistency in Time to Response with Upadacitinib as Monotherapy or Combination Therapy and Across Patient Populations with Rheumatoid Arthritis
    Rubbert-Roth, Andrea
    Combe, Bernard
    Szekanecz, Zoltan
    Hall, Stephen
    Haraoui, Boulos
    Attar, Suzan Mansour Hussein
    Ekwall, Anna-Karin
    Song, Yanna
    Shaw, Tim
    Nagy, Orsolya
    Xavier, Ricardo
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1717 - 1719
  • [39] Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial
    van Vollenhoven, Ronald
    Strand, Vibeke
    Takeuchi, Tsutomu
    Chavez, Nilmo
    Walter, Pablo Mannucci
    Singhal, Atul
    Swierkot, Jerzy
    Khan, Nasser
    Bu, Xianwei
    Li, Yihan
    Penn, Sara K.
    Camp, Heidi S.
    Aelion, Jacob
    ARTHRITIS RESEARCH & THERAPY, 2024, 26 (01)
  • [40] CONSISTENCY IN TIME TO RESPONSE WITH UPADACITINIB AS MONOTHERAPY OR COMBINATION THERAPY AND ACROSS PATIENT POPULATIONS WITH RHEUMATOID ARTHRITIS
    Rubbert-Roth, A.
    Combe, B.
    Szekanecz, Z.
    Hall, S.
    Haraoui, B.
    Attar, S.
    Ekwall, A. K. H.
    Song, Y.
    Shaw, T.
    Nagy, O.
    Xavier, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 613 - 614
12345